Catalog Number
ACM112356-3
Description
Polyethylene glycol (PEG) compounds contain a polyether unit, commonly expressed as R1-(O-CH2-CH2)n-O-R2. They are generally biocompatible, non-toxic and stable in both organic and aqueous solutions, and so are extensively used in biological applications, as well as nanotechnology and materials research. Proteins with PEG chain modifications and compounds encapsulated in PEG liposomes exhibit a longer half-life in vivo than their non-PEGylated counterparts, a phenomenon known as PEG shielding. Functionalised PEG lipids and phospholipids can be used for protein-PEG conjugation.
IUPAC Name
2-[2-(2-methoxyethoxy)ethoxy]ethanol
Molecular Formula
C7H16O4
Canonical SMILES
COCCOCCOCCO
InChI
InChI=1S/C7H16O4/c1-9-4-5-11-7-6-10-3-2-8/h8H,2-7H2,1H3
InChI Key
JLGLQAWTXXGVEM-UHFFFAOYSA-N
Boiling Point
122 °C at 10 mmHg (lit.)
Melting Point
-45°C (lit.)
Purity
purum, ≥97.0% (GC)
Density
1.026 g/mL at 25 °C (lit.)
Solubility
6.09 M;In water, miscible;Soluble in water;Solubility in heptane = 1.5 wt%, completely soluble in acetone, benzene, ethyl ether, methanol, and carbon tetrachloride at 25 °C.;Solubility in water: miscible
Application
Activated PEG derivatives can be used to modify peptides, proteins, or in other bioconjugation applications. PEGylated materials have found broad use in drug delivery systems, virology, and immunology, as the incorporation of PEG improves pharmacological properties such as increased water solubility, enhanced resistance to degradation (protein hydrolysis), increased circulation half-life, and reduced antigenicity. In addition to PEGylation, activated PEG derivatives can also be used to form networks for tissue engineering or drug delivery applications, depending on the architecture and reactivity.
Covalently-Bonded Unit Count
1
Linear Formula
CH3(OCH2CH2)3OH
Monoisotopic Mass
164.10485899
Topological Polar Surface Area
47.9 Ų
Viscosity
7 centistokes at 25 °C